Rosalind Advisors Inc. Lowers Stock Holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD)

Rosalind Advisors Inc. cut its holdings in shares of Clearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) by 95.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 127,220 shares of the company's stock after selling 2,465,373 shares during the quarter. Clearside Biomedical accounts for approximately 0.1% of Rosalind Advisors Inc.'s holdings, making the stock its 28th biggest holding. Rosalind Advisors Inc. owned approximately 0.17% of Clearside Biomedical worth $162,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in Clearside Biomedical by 14.5% during the 1st quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company's stock valued at $3,811,000 after purchasing an additional 314,480 shares during the period. Renaissance Technologies LLC raised its holdings in Clearside Biomedical by 6.6% in the 2nd quarter. Renaissance Technologies LLC now owns 582,689 shares of the company's stock worth $757,000 after acquiring an additional 35,900 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Clearside Biomedical during the 2nd quarter valued at about $368,000. XTX Topco Ltd grew its holdings in shares of Clearside Biomedical by 172.2% in the second quarter. XTX Topco Ltd now owns 54,313 shares of the company's stock worth $71,000 after acquiring an additional 34,359 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in Clearside Biomedical during the first quarter valued at approximately $49,000. 18.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on CLSD shares. Chardan Capital reissued a "buy" rating and set a $6.00 price target on shares of Clearside Biomedical in a report on Monday, October 14th. StockNews.com upgraded shares of Clearside Biomedical from a "sell" rating to a "hold" rating in a report on Friday, October 18th. HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Clearside Biomedical in a report on Tuesday, August 27th. Finally, Needham & Company LLC increased their target price on shares of Clearside Biomedical from $4.00 to $6.00 and gave the company a "buy" rating in a research report on Thursday, October 10th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $5.17.

Insider Activity at Clearside Biomedical

In related news, insider Ngai Hang Victor Chong purchased 36,500 shares of the company's stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $1.00 per share, for a total transaction of $36,500.00. Following the completion of the purchase, the insider now directly owns 100,000 shares of the company's stock, valued at approximately $100,000. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 9.20% of the stock is currently owned by corporate insiders.

Clearside Biomedical Trading Up 0.9 %

NASDAQ CLSD traded up $0.01 during trading hours on Wednesday, reaching $1.08. The company had a trading volume of 215,163 shares, compared to its average volume of 404,687. The stock has a market capitalization of $80.71 million, a P/E ratio of -2.16 and a beta of 2.33. The stock has a 50-day moving average of $1.18 and a 200 day moving average of $1.20. Clearside Biomedical, Inc. has a 1-year low of $0.76 and a 1-year high of $2.12.

Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.04. The company had revenue of $0.09 million during the quarter, compared to analysts' expectations of $0.25 million. During the same quarter in the previous year, the business posted ($0.15) EPS. As a group, sell-side analysts predict that Clearside Biomedical, Inc. will post -0.56 EPS for the current year.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.